|
Sign In to gain access to subscriptions and/or personal tools.
|
Central nervous system lymphoma associated with mycophenolate mofetil in lupus nephritis
N Dasgupta
Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
A C Gelber
Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
F Racke
Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
D M Fine
Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA, dfine1{at}jhmi.edu
Lymphomas, both within and outside the central nervous system, are uncommon among patients with systemic lupus erythematosus (SLE). We describe a 58-year old Korean woman with SLE who presented with acute headache and confusion in the setting of prednisone and mycophenolate mofetil (MMF) therapy used to treat focal proliferative and membranous lupus nephritis. Three-dimensional brain magnetic resonance imaging (MRI) showed two peripherally (ring) enhancing lesions within the basal ganglia, bilaterally, with associated mass effect and subfalcine herniation. A brain biopsy revealed an Epstein-Barr virus (EBV)-positive diffuse large B cell lymphoma. This is the first description of CNS lymphoma in a patient treated with MMF for lupus nephritis. While intracerebral lymphoma in the immunocompromised patient with lupus is rare, this disorder should be considered in the differential diagnosis of new-onset neurological symptoms among such patients.
Key Words: central nervous system lymphoma immunosuppression lupus nephritis mycophenolate mofetil systemic lupus erythematosus
Lupus, Vol. 14, No. 11,
910-913 (2005)
DOI: 10.1191/0961203303lu2179cr

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati Twitter What's this?
This article has been cited by other articles:

|
 |

|
 |
 
A. Jacob, M. Matiello, B. G. Weinshenker, D. M. Wingerchuk, C. Lucchinetti, E. Shuster, J. Carter, B. M. Keegan, O. H. Kantarci, and S. J. Pittock
Treatment of Neuromyelitis Optica With Mycophenolate Mofetil: Retrospective Analysis of 24 Patients
Arch Neurol,
September 1, 2009;
66(9):
1128 - 1133.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F Falcini, S Capannini, G Martini, F La Torre, A Vitale, F Mangiantini, F Nacci, M. Cerinic, R Cimaz, and F Zulian
Mycophenolate mofetil for the treatment of juvenile onset SLE: a multicenter study
Lupus,
February 1, 2009;
18(2):
139 - 143.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Kumar, P. Sandroni, D. P. Steensma, H. S. Luthra, and T. M. Habermann
POLYRADICULOPATHY DUE TO METHOTREXATE-INDUCED EBV-ASSOCIATED LYMPHOPROLIFERATIVE DISORDER
Neurology,
November 11, 2008;
71(20):
1644 - 1645.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. J. Gerbino, C. H. Goss, and J. A. Molitor
Effect of Mycophenolate Mofetil on Pulmonary Function in Scleroderma-Associated Interstitial Lung Disease*
Chest,
February 1, 2008;
133(2):
455 - 460.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. P. O'Neill, S. Vernino, A. Dogan, and C. Giannini
EBV-associated lymphoproliferative disorder of CNS associated with the use of mycophenolate mofetil
Neuro-oncol,
July 1, 2007;
9(3):
364 - 369.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P F Finelli, K Naik, J A DiGiuseppe, and A Prasad
Primary lymphoma of CNS, mycophenolate mofetil and lupus
Lupus,
December 1, 2006;
15(12):
886 - 888.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
A Doria, L Iaccarino, S Arienti, M E Rampudda, M G Canova, R Rondinone, and S Todesco
Mycophenolate mofetil and systemic lupus erythematosus
Lupus,
November 1, 2006;
15(11_suppl):
44 - 54.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
A Sinclair and R Baildon
Mycophenolate mofetil: an overview
Lupus,
November 1, 2006;
15(11_suppl):
70 - 77.
[PDF]
|
 |
|
|
|